Clinical Trials on HIV-1 Infection in United Kingdom

Total 25998 results

Imperial College London
Medical Research Council

Terminated

Novel Interventions in HIV-1 Infection (IMIRC1003)

HIV-1 Infection

United Kingdom
Imperial College London

Active, not recruiting

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens (EAVI2020_01)

HIV-1-infection

United Kingdom
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
Gilead Sciences; ViiV Healthcare

Completed

The Role of Home Packs of HIV PEPSE in High Risk Individuals (Home PEPSE)

HIV-1-infection

United Kingdom
Brighton and Sussex University Hospitals NHS Trust
Merck Sharp & Dohme LLC

Completed

The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients (MOR)

HIV-1-infection

United Kingdom
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
Objectif Recherche Vaccins SIDA
Merck Sharp & Dohme LLC; Pfizer; Cytheris SA

Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)

HIV-1 Infection

United Kingdom, France, Italy, Spain
Ratiopharm GmbH

Completed

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

HIV-1

United Kingdom
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Chelsea and Westminster NHS Foundation Trust

Recruiting

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

HIV-1-infection

United Kingdom
University of Oxford
Medical Research Council

Terminated

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

HIV-1

United Kingdom
ANRS, Emerging Infectious Diseases
Imperial College London; University College, London; Fred Hutchinson Cancer Center and other collaborators

Terminated

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection (EHVAT01)

HIV-1-infection

Switzerland, United Kingdom
University of Oxford

Completed

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (HIV-CORE 002)

HIV-1 Infections

United Kingdom
Gilead Sciences

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

HIV-1 Infection

France, United Kingdom, Spain, Belgium, Ireland
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
University College, London
Medical Research Council; Royal Free Hospital NHS Foundation Trust; ViiV Healthcare

Completed

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV (MAVMET)

Hepatic Steatosis | HIV-1-infection

United Kingdom
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Nina Bhardwaj
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Completed

Enhancement by Poly-ICLC During HIV-1 Infection (Poly-ICLC)

HIV-1 Infected Adults With Chronic HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Chelsea and Westminster NHS Foundation Trust

Recruiting

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

HIV-1-infection

United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
CytoDyn, Inc.

Completed

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

HIV Infections | HIV -1 Infection

United States
Pfizer
ViiV Healthcare

Terminated

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

HIV-1

South Africa, Australia, United Kingdom, Canada, Italy, Poland, Switzerland, Mexico, Brazil
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

HIV-1-infection

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

HIV-1 Infection

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

HIV-1 Infection

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults (M&M)

HIV-1 Infection

United States
Massachusetts General Hospital
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects (PARC002)

HIV Infections | HIV-1 Infection

United States
GeoVax, Inc.
University of Alabama at Birmingham; AIDS Research Consortium of Atlanta; AIDS...

Completed

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

HIV-1 Infection

United States
Northwestern University
Pfizer; Tibotec, Inc

Completed

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 (MIDAS)

HIV Infections | HIV-1 Infection

United States
ANRS, Emerging Infectious Diseases
University College London Hospitals; Hospital Clinic of Barcelona; Imperial College... and other collaborators

Completed

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

HIV-1-infection

France, United Kingdom, Switzerland
Allegheny Singer Research Institute (also known...

Active, not recruiting

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (CAPRI)

HIV Infections | HIV-1-infection | HIV I Infection

United States
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
International Partnership for Microbicides, Inc.

Completed

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

HIV-1 Infections

United States
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)

Completed

Providing Unique Support for Health (PUSH) Study

HIV-1-infection

United States
Environment and Health Group, Inc.
Prisma Health

Completed

mHealth for ART Adherence by HIV+ African Americans

HIV-1-infection

United States
City of Hope Medical Center

Terminated

Gene Transfer for HIV Using Autologous T Cells (Gene Transfer)

HIV-1 Infection

United States
Brigham and Women's Hospital
Merck Sharp & Dohme LLC

Terminated

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

HIV-1 Infection

United States
Rockefeller University

Completed

DCVax Plus Poly ICLC in Healthy Volunteers

HIV Infection | Healthy Volunteers | HIV-1 Infection

United States
Janssen R&D Ireland

Completed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Australia, France, United Kingdom, China, Belgium, Germany, Spain, Argentina, Romania, South Africa, Canada, Denmark, Netherlands, Chile, Puerto Rico, Austria, Russian Federation, Thailand, Sweden, Taiwan
Viriom

Completed

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

HIV-1-infection

United States
Southampton Healthcare, Inc.

Terminated

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

HIV-1-infection

United States
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
The University of Texas Health Science Center,...

Completed

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

HIV-1-infection

United States
Emory University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Researching Alveolar Macrophage Improvements With Supplements in HIV (RAISe)

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
Tulika Singh, MD
Gilead Sciences

Recruiting

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

HIV-1-infection

United States

Clinical Trials on HIV-1 Infection in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations